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Abstract: Three decades have passed since a series of studies indicated that the aging 
kidney was characterized by increased susceptibility to nephrotoxic injury. Data from   
these experimental models is strengthened by clinical data demonstrating that the aging 
population has an increased incidence and severity of acute kidney injury (AKI). Since 
then a number of studies have focused on age-dependent alterations in pathways that 
predispose the kidney to acute insult. This review will focus on the mechanisms that   
are altered by aging in the kidney that may increase susceptibility to injury, including 
hemodynamics, oxidative stress, apoptosis, autophagy, inflammation and decreased repair. 
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1. Introduction 
During the last century, human lifespan has increased substantially resulting in a substantial 
increase of elderly people over the next two decades [1]. Individuals aged 65 years or more represented 
12.8% of US population in 2008 [2]. By 2030, the number of elderly people is expected to be 71 million, 
accounting for 21% of US population [3]. In fact, the elderly population is the most rapidly growing 
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population segment in the western world [4]. It is estimated that by 2025, there will be over 800 million 
individuals over the age of 65 worldwide [5]. Thus, the study of age-dependent pathophysiology,  
and translation of these findings to the clinic, is a significant challenge for biomedical sciences in the 
21st century. 
Acute kidney injury (AKI), previously called acute renal failure (ARF) [6], is defined as an abrupt 
onset of renal dysfunction ranging from minor loss of function to failure [7–9]. AKI is a common 
clinical complication that develops in approximately 4%–7% of hospitalized patients each year and the 
prognosis can be poor [10,11]. While the mortality rates for AKI are decreasing, the mortality range 
remains from 20%–35% [12,13] and “nearly 2 out of 3 patients suffering from ARF will not be alive 
90 days after the onset of ARF” [14]. Thus, AKI remains a significant public health problem.   
A relationship between AKI and the elderly has long been recognized [15–17]. In 1972, studies 
suggested that 23.8% of patients with AKI were over the age of 60 [15] and the following year it was 
shown that 13.7% were older than 70 [16]. In 1987, these percentages had risen to 76% and 46%, 
respectively [17]. The increasing prevalence of elderly AKI patients is supported by additional studies; 
Turney et al. [18] showed that the median age of AKI patients was 41.25 years in the 1950s and 
increased to 60.5 in the 1980s. In a study by Rosenfeld et al., the average age of those who succumbed 
to AKI was 71.9 ± 8.8 years old, demonstrating the importance of the relationship between aging  
and AKI [17]. While this relationship has been established for four decades, interest in this area has 
dramatically increased and AKI in the elderly has been the subject of several recent reviews [19–23]. 
In this review, we will address the evidence that demonstrates the strong linkage between aging and 
AKI and the insight into mechanisms underlying this effect. 
2. Aging and AKI: Clinical Evidence 
In the past twenty-five years, a number of studies have associated aging with a higher risk for  
AKI [24,25]. Pascual et al. performed a study in Spain demonstrating that the incidence of AKI is 3.5 times 
higher in patients over 70 than those under 70; patients older than 80 years old were 5.0 times more 
likely to develop AKI [26]. Age above 65 years has also been shown to be an independent risk factor 
for AKI in a multinational, multicenter study [27]. Balardi and colleagues have shown that elderly 
patients (≥65 years) had ten times the incidence rate of AKI compared with those less than   
65 years of age in Italy [28]. Xue et al. established age as a risk factor for AKI; the incidence of AKI 
was 1.9% in patients younger than 65 and rose to 2.9% in those older than 85 [13]. Data from a 
community-based cohort in California showed that the incidence of AKI not requiring dialysis was  
79 per 100,000 person-years in patients younger than 50 and 3545 in patients over 80 [29]. Most 
recently, an increase in AKI in the elderly was seen following crush injury due to the earthquake in 
Wenchuan, China in 2008; compared to the resident population, the elderly patient with crush-related 
AKI was 2.6-fold higher than the younger patients [30]. Moreover, AKI that develops in the elderly is 
more severe and the patient is less likely to recover. Venkatachalam et al. showed that the percentage 
of elderly patients who did not recover renal function was 31.3% compared with 26% of younger 
cohorts [31]. Hospitalized AKI patients requiring dialysis are older than their counterparts who do not 
require dialysis (63.4 vs. 47.6 years) [32,33]. No increase in mortality has been consistently   Int. J. Mol. Sci. 2014, 15  15360 
 
 
reported [17,24,34–37]; however, studies have suggested that mortality following AKI is increased in 
the elderly [15,38]. 
3. Aging and AKI: Experimental Models 
A number of animal studies in the 1980s indicated that the aging kidney has a greater susceptibility 
to both ischemic and toxic injuries. Many of these studies used rats and it must be noted that due to the 
progressive nephropathy in senescent rats, they may not represent the optimal model to investigate 
xenobiotic-induced injury [39]. Beierschmidt et al. demonstrated an age-related increase in acetaminophen 
nephrotoxicity in male Fischer 344 rats, comparing rats at 2–4, 12–14 and 22–25 months of age [40]. 
Interestingly, baseline BUN, urine osmolality and urine volume were similar in all groups, suggesting 
that a major component of aging was increased sensitivity to insult as opposed to an overt loss of renal 
function. The nephrotoxicity of gentamicin is increased in the aging rat with no alteration in the 
pharmacokinetics of the antibiotic [41]. These findings were verified with female rats, but suggested 
that the lack of a relationship between the loss of renal function (decreased glomerular filtration rate 
(GFR)) and tubular injury (necrosis or casts) indicated that age-related changes reflected alterations in 
renal hemodynamics, rather than differences in the tubular susceptibility to injury [42]. In contrast, 
however, Miura et al. [43] demonstrated that slices of kidney from old rats were more susceptible to  
in vitro anoxia (100% nitrogen) than slices from young counterparts as assessed by organic anion 
transport in the proximal tubules, leading the authors to conclude that a component of the increased 
sensitivity to injury involves age-dependent alterations in the proximal tubules. Previous studies in our 
laboratory also showed similar results that renal slices from aged Fischer 344 rats fed ad libitum, but 
not aged caloric-restricted male animals, were more susceptible to ischemic injury (100% nitrogen) when 
compared with slices from young animals as assessed by histological and biochemical evaluations [44]. 
These ex vivo studies again demonstrated that the proximal tubular epithelial cells had an inherent 
increase in susceptibility to injury. Aged Wag/Rij rats (23–26 months) are more sensitive to tobramycin, 
an aminoglycoside antibiotic, as evidenced by tubular necrosis and urinary NAG levels [45]. More 
recent studies have extended age-dependent AKI models to the mouse. The aging (46–49 weeks) male 
C57Bl/6 mice exhibited prolonged elevation of plasma creatinine and greater mortality after bilateral 
renal ischemia-reperfusion (I/R) induced AKI compared to the young (8–10 weeks) [46]. Star and 
colleagues [47] developed a sepsis-induced AKI model by cecal ligation puncture (CLP) using aged 
(10.5–11 months) mice. Lipopolysaccharide (LPS) induced an increase in BUN and creatinine in the 
aged, but not young mice, setting the stage for the development of the more complex, clinically 
relevant CLP model. These results indicate that laboratory models recapitulate the clinical scenario of 
age-related AKI in humans and allow for the elucidation of specific mechanisms. 
4. Aging and AKI: Causes 
4.1. Chronic Kidney Disease (CKD) 
It is well established that aging is associated with structural and functional renal changes (Figure 1) [48]. 
It has been stated that “with the possible exception of the lung, the changes in kidney function with 
normal aging are the most dramatic of any human organ or organ system” [49,50]. The normal kidney Int. J. Mol. Sci. 2014, 15  15361 
 
 
loses about 20%–25% of its mass during aging, with the loss involving both cortical glomeruli and 
tubules [51]. Age-dependent decline in kidney volume was not detectable by imaging, possibly   
due to the compensatory hypertrophy of functional nephrons [52,53]. In addition to nephron loss, 
glomerulosclerosis and tubulointerstitial fibrosis define the aging kidney [54,55]. There is also an 
increasing incidence of nephrosclerosis with aging from 2.7% for people aged 18–29 years to 73% for 
people aged 70–77 years [56]. Functionally, the aging kidney has a parallel decline in both glomerular 
and tubular function [57]. The seminal Baltimore longitudinal study demonstrated an average of   
0.75 mL/min yearly decline in GFR in 254 men without hypertension or kidney disease [58]. A similar 
rate of decline (0.63 mL/min/year) was reported in a recent study based on 1203 living kidney   
donors [56]. The GFR loss rate is tripled in subjects over 40 as compared with those under 40 in the 
Baltimore study [58]. A more recent study in healthy Chinese people described similar results [59]. 
Figure 1. Causes of increased incidence of acute kidney injury (AKI) with aging. 
 
Approximately 35% of the elderly US population has stage 3 CKD [3] and an increasing number of 
elderly with CKD developed the end-stage kidney disease (ESKD) which requires dialysis [60]. There 
is a growing recognition that AKI most often occurs on a background of CKD [12,61]. Elderly patients 
who developed AKI on a background of CKD are less likely to recover from AKI and more likely to 
progress to more advanced stage or even ESKD which contributes to the higher mortality rate [62,63]. 
The hazard ratio of developing ESKD for patients with both AKI and CKD is 13.0 relative to those 
only with AKI [64]. The two-year mortality rate is higher for those with AKI and CKD (64.3%)  
than those with AKI alone (54.3%) [64]. On the other hand, AKI also predisposes patients to CKD 
after tubular regeneration due to inflammatory responses, paracrine stimulation of myofibroblasts, 
epithelial cell senescence, and loss of cellular plasticity, all of which promote a pro-fibrogenic 
phenotype [65,66]. Int. J. Mol. Sci. 2014, 15  15362 
 
 
4.2. Medications 
Older individuals more commonly develop diabetes mellitus, hypertension, atherosclerosis, and 
heart failure, each of which can directly increase the risk of AKI [32]. These comorbidities can also 
increase the risk of AKI indirectly by leading to increased medication use (Figure 1) in elderly patients 
as compared with younger patients [63]. Around 20% of the episodes of AKI are induced by 
nephrotoxic drugs and the incidence of drug-induced nephrotoxicity leading to AKI among elderly in 
the hospital can be as high as 66% [67,68]. 
Potassium homeostasis is regulated, in part, by excretion of potassium into the urine via active 
secretion by principal cells in the collecting tubule; aldosterone is an important part of this control 
system. The direct aldosterone response to a potassium load is diminished in aging patients which 
increases vulnerability to hyperkalemia [69]. As a result, drug-induced hyperkalemia is more prevalent 
in aging patients [70]. 
AKI secondary to non-steroidal anti-inflammatory drugs (NSAIDs) is more common in the   
elderly [71]. More than 80% of patients with NSAID induced AKI are over the age of 60 [72]. In a 
study with patients aged 50–84 years, the relative risk (RR) for AKI was 3.2 in NSAID users and was 
increased dramatically when NSAIDs were used in combination with diuretics (RR 11.6) and calcium 
channel blockers (RR 7.8) [73]. The combination of NSAIDs and angiotensin-converting enzyme 
(ACE) inhibitors was also demonstrated to be associated with nephrotoxicity in elderly patients   
(>75 years) [74]; The incidence of aminoglycoside-induced nephrotoxicity is also elevated in the 
elderly [75,76] and increased injury in response to aminoglycosides in combination an ACE inhibitor 
in elderly patients has been reported [77]. While contrast-induced nephropathy (CIN) is a significant 
cause of AKI in hospitalized elderly patients [68,78], age per se may not be an independent predictor 
of contrast nephropathy [79]. It is expected that CIN will remain an important cause of AKI in the 
elderly due to the increased use of contrast media in this population [80]. 
5. Aging and AKI: Mechanisms 
The impact of kidney aging on pharmacokinetics has long-been recognized and is the subject of 
many reviews [76,81]. Importantly, the T1/2 of a number of drugs with potential adverse effects on  
the kidney, including NSAIDs and antibiotics, is increased in elderly patients [82]. As such, the 
increased nephrotoxicity of cephaloridine, a broad spectrum antibiotic, in aging male Fischer 344   
rats (27–29 and 10–12 months compared to 2.5 months) is associated with increased serum and   
cortical concentrations of the antibiotic [83]. However, the cortical concentrations were similar in the 
10–12 and 27–29 month rats, while proximal tubule dysfunction, as assessed by tubular transport, was 
worse in the older rats, suggesting that there is an increased sensitivity of the aging proximal tubular 
epithelium to injury. This highlights the fact that AKI in the elderly is multifactorial, involving a 
number of potential mechanisms that we will attempt to delineate (Figure 2). 
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Figure 2. Mechanisms of increased incidence of AKI with aging. 
 
5.1. Hemodynamics 
Hypovolemia, both true (dehydration, bleeding, vomiting, diarrhea) and functional (cardiac impairment, 
liver disease, nephrotic syndrome) is common in elderly patients [84]. Until about the fourth decade, 
renal blood flow is maintained at approximately 600 mL/min. It then drops by approximately 10% 
every decade due to the activation of sympathetic nervous system, renin-angiotension-aldosterone 
system and vasopressin secretion [62,85]. The aging rat kidney is characterized by focal loss of 
peritubular capillaries spatially associated with tubulointerstitial injury [86,87], which contributes to 
chronic hypoxia in the aging kidney [88]. 
A role of nitric oxide (NO) in the increased sensitivity of the aging kidney to injury has been 
established. Reduced NO in peritubular capillaries in the aging kidney has been demonstrated   
which contributes to increased vasoconstriction, sodium retention, mesangial fibrosis and matrix 
production [86,89]. Increased I/R injury in aged (18 months) rats as compared to young (3 months) rats 
was associated with a dramatic increase in vasoconstriction in the aged rats. L-arginine, the precursor 
of NO synthesis, attenuated injury in aged rats to a greater extent than the young ones [90]. Taken 
together, these results suggest that the aging is associated with decreased NO levels which exacerbate 
I/R injury. Later studies demonstrated that NO levels, as well as acetylcholine-induced vasodilation, 
are reduced in the aging rat kidney [91]. These results were strengthened when it was shown   
that atorvastatin which enhances NO bioavailability in the aging rats afforded protection against I/R 
injury [92]. Another factor in the diminished NO-mediated responsiveness is the increased levels of  
the endogenous nitric oxide synthase (NOS) inhibitor, asymmetric dimethylarginine, in aging rats [93] 
and humans [94]. The increased nephrotoxicity of gentamicin has also been postulated to involve 
decreased NO production, as glomerular nitrate levels are decreased in aged rats (12 months) as compared Int. J. Mol. Sci. 2014, 15  15364 
 
 
to young controls [95]. In elderly patients (81–96 years), NO did not increase after vasodilatory   
stimuli [96]. 
In addition, the aging kidney has diminished responsiveness to vasodilators and increased   
sensitivity to vasoconstrictors [97]. Vasodilators, including pyrogen and acetylcholine [98], ANP [99], 
dopamine [100] and amino acids [100,101], have decreased functionality in the aging kidney.   
This decreased vasodilatation is coupled with increased vasoconstrictive response to sympathetic 
activation [102] or AngII [103]. Clinically, prolonged vasoconstriction due to contrast administration 
is associated with acute renal dysfunction in elderly patients [78]. Taken together, these data suggest 
the normal vascular response is impaired in the aging kidney, and this contributes to the increased AKI. 
5.2. Oxidative Stress 
The data regarding the role of antioxidants in age-dependent AKI is ambiguous. Although glutathione 
S-transferase (GST) activity is lower (45% of control) in aged rat kidneys compared to middle-aged 
and young rats, renal glutathione (GSH) levels are not decreased in the aging rat kidney [40]. We have 
confirmed that basal GSH levels are not lower in the aging kidney, but levels are depleted more rapidly 
when challenged with acute stress [44]. Several studies suggest that deficiencies within the antioxidant 
defense systems may play a role in the aging kidney. A decrease in catalase levels (41% of young) was 
seen in male Wistar rats at 15 months as compared to 10 and 2.5 month rats; no difference was seen at 
10 months as compared to 2.5 [104]. Total plasma antioxidant potential is reduced in aging rats; this 
may explain the marked increase in oxidative stress (8-hydroxy-2'-deoxyguanosine levels) in the kidney 
following I/R injury in aged animals [105]. In a study comparing young (3 months), middle-aged  
(12 months) and aged male (24 months) Wistar rats, I/R injury (as assessed by inulin clearance as  
a measure of GFR) was more severe in the middle-aged and aged rats [106]. Interestingly, lipid 
peroxidation was elevated at baseline in middle-aged and aged rats and 30 days supplementation   
with vitamin E attenuated I/R injury in these rats [106]. The vitamin E supplementation, however, 
could represent a sub-chronic adaptation, rather than a direct protective effect against acute injury. 
Furthermore, superoxide dismutase (SOD) attenuated I/R injury in aged rats to a greater extent than the 
young ones [90]. The induction of hemeoxygenase-1 (HO-1) was blunted in aging mice (12 months old) 
following I/R injury and the injury was worse in the aging mice [107]. Interestingly, HO-1 was localized 
to interstitial macrophages, suggesting that they may have a renoprotective role. Overexpression of Sirt1, 
a NAD-dependent protein deacetylase, in the proximal tubule cell maintains peroxisome number and 
reduces renal reactive oxygen species levels which rescued cell apoptosis induced by cisplatin [108]. 
Downregulation of Klotho gene, an anti-aging gene expressed in the distal convoluted tubules, was 
observed in aging kidney. This was associated with increased susceptibility to oxidative stress via 
activation of the insulin growth factor-1(IGF-1) pathway [31]. Taken together, these data suggest that 
decreased antioxidants and increased oxidative stress may play a role in age-dependent AKI; however, 
significant work remains to elucidate the specific pathways, as well as potential cell-specific effects. 
5.3. Mitochondria/Apoptosis 
Increased cell death due to apoptosis is an intriguing hypothesis for enhanced cell injury with aging, 
as it represents a convergence between chronic renal dysfunction due to tubular loss and increased AKI Int. J. Mol. Sci. 2014, 15  15365 
 
 
in the aging kidney. As such, an increase in salicylate-induced nephrotoxicity was seen in 12 month 
old rats, as compared to young controls (3 months) [109]. Interestingly, there was evidence of an 
increased sensitivity of the mitochondria in the proximal tubular epithelial cells to injury. Further 
evidence for a role of the mitochondria comes from a study of I/R injury in aged (27 months) Wistar 
rats [110]. Tubular cell apoptosis was increased in aged rats as compared to young controls; basal 
levels of cytosolic cytochrome C, active caspase-3/9 were elevated in the aging kidney and the   
up-regulation following I/R injury of caspase-3/9 was increased in aged rats [111]. Increased 
expression of Bax, a pro-apoptotic protein, caspase-3/9 and cytochrome C in the aging kidney have 
been observed in other studies [112,113]. The expression of Bcl-2, which is an apoptosis inhibitor, 
however, is decreased in aged rat kidney [112]. Moreover, the expression of p21, a cyclin-independent 
kinase (CDK) inhibitor, which induces apoptosis is increased in aged rats [114]. Higher levels of  
p53 and p21 were expressed in the aging male C57Bl/6 mice after bilateral renal I/R-induced   
AKI [46]. Therefore, increased apoptotic cell death could account, in part, for the increased AKI in  
the aging kidney. 
5.4. Autophagy 
Autophagy is an evolutional conserved process to recycle damaged organelles [115,116]. Recent 
literature suggests a protective role for autophagy in both I/R-induced and toxicant-mediated AKI [117]. 
The autophagic removal of damaged mitochondria in the mitochondria-rich proximal tubule cells   
plays a critical role in protecting against AKI [117]. In the aging male Fischer 344 rat, Atg7 was 
downregulated, as was LC3, indicating that autophagic function is decreased [118]. In the aging male 
C57Bl/6 mice, autophagic activity was also diminished [116]. Cui et al. demonstrated that autophagy 
is not induced during ischemic stress by renal proximal tubule cells in the aging kidney, and argued 
that this contributes to the development of AKI [118]. Pharmacologic induction of autophagy by 
administrating the mTOR inhibitor, rapamycin or temsirolimus, facilitated renal recovery from AKI 
during endotoxemia in aged mice [116,119] and pharmacologic inhibition of autophagy with either 
bafilomycin or 3-methyladenine enhanced cisplatin-induced renal tubular cell death [120]. More 
severe morphologic derangements and greater elevation in serum creatinine levels were observed in 
proximal tubule-specific autophagy-deficient mice in response to I/R or cisplatin injury [117,119,121]. 
These data suggest that autophagy, and its role in AKI, represent a novel and fruitful area to be 
explored in the aging kidney. 
5.5. Inflammation 
Aging is associated with chronic inflammation [122,123] which is characterized by progressive 
accumulation of lymphocytes and macrophages in renal interstitium [121]. Since inflammation is a 
well-established mediator of AKI [124,125], a role for inflammation in age-related AKI is highly 
plausible. A higher influx of lymphocytes and macrophages was detected, accompanied by an increase 
in tumor necrosis factor-α (TNF-α) and monocyte chemoattractant protein-1 (MCP-1) mRNA 
expression in aged kidney following transient ischemic injury [46]. In microarray-based analyses of 
the aging kidney, both human [126], and rat [44], a large percentage of the up-regulated genes were 
linked to inflammation. In another microarray-based study, the aging kidney was shown to be marked Int. J. Mol. Sci. 2014, 15  15366 
 
 
by inflammatory cell infiltration, as demonstrated by the dramatic increase in expression of B- and  
T-cell specific genes [127]. In both the human and rat microarrays, MMP-7 was shown to be 
significantly up-regulated; in addition to its proteolytic function, MMP-7 has a pro-inflammatory   
role [128]. The role of specific pro-inflammatory mediators in the aging kidney, and their relationship 
to AKI, is an area that will demand future attention. Importantly, AKI-induced inflammation can also 
promote renal senescence. AKI induces inflammatory cytokines that enhance extracellular matrix 
deposition, fibrosis and cell apoptosis [65,129]. Recently, a transcriptomics study unveiled AKI 
induces TWEAK engagement of Fn14 which promotes inflammation via secretion of CXCL16 in renal 
tubular cells and suppression of anti-aging hormone Klotho through an NF-κB dependent manner, 
thereby mechanistically linking AKI with aging [130]. 
5.6. Repair 
Given that the clinical evidence suggests that AKI is associated with delayed, or decreased, repair  
in the elderly, there has been a recent surge of work examining aging and kidney repair [31,112].  
Baraldi et al. suggested that complete recovery was reduced in the elderly patients [28]. Arora et al. 
demonstrated that recovery from AKI, as determined by time to normalization of serum creatinine,  
was three-times as long in elderly (mean 67.1) compared to young (32.3) patients (32 vs. 11.4 days, 
respectively) [37]. Schmitt et al. examined data from 17 studies of AKI and found that a higher 
percentage of surviving elderly (>65 years) patients did not recover renal function as compared to 
younger patients; the RR was 1.28 (95% confidence interval of 1.06–1.55) [112]. Fortunately, data 
from animal studies are in agreement with the clinical findings. In a seminal study, Cantley and 
coworkers demonstrated that zinc-α(2)-glycoprotein (Zag), an inhibitor of epithelial cell proliferation, 
is elevated (6.4-fold) in proximal tubular epithelial cells from aged mice (19–24 months) [131]. 
Overexpression of Zag decreased proliferation of proximal tubular epithelial cells in vitro and, 
importantly, knockdown of Zag in the kidneys of aged mice using siRNA increased proliferation 
following I/R injury in vivo. Additionally, Zag knockdown increased peritubular deposition of collagen 
IV which was hypothesized to attenuate recovery. 
Several mechanisms may underlie the decreased repair potential of the aging kidney. Miya et al. 
have shown that decrease in DNA synthesis was seen following I/R injury in the aging kidney [87]. 
The expression of P16
INK4A, a CDK4/6 inhibitor that can block cell-cycle, is increased in epithelial and 
interstitial cells of aging human and mouse kidneys [132,133]. Ablation of P16
INK4A resulted in 
proliferation and improved regeneration following ischemic injury [134]. Moreover, the expression of 
p21, another CDK inhibitor which inhibits cell proliferation, is increased in aged rats [114]. The 
increased expression of p21 and P16
INK4A can be accompanied by the accumulation of Cyclin D1 
which might reflect an abnormal G1-S transition [135,136]. Furthermore, both p21 and P16
INK4A 
enhance telomere shortening, promoting the senescence of renal tubules [137]. Telomere shortening 
was also observed in the aging human kidney and is more pronounced in cortex [138]. 
Growth factors are critical mediators in kidney repair [139]. The expression of factors promoting 
angiogenesis, cell proliferation and cell recruitment such as vascular endothelial growth factor 
(VEGF), epidermal growth factor (EGF) and insulin-like growth factor (IGF)-1, decline in the aging 
kidney [140–142]. By contrast, the expression of pro-fibrotic growth factors, including TGF-β1, Int. J. Mol. Sci. 2014, 15  15367 
 
 
connective tissue growth factor (CTGF) and integrin-linked kinase (ILK) are increased in the aging 
kidney [114,143]. These data demonstrate an imbalance of growth factor expression which favors the 
development of tubulointerstitial fibrosis and an anti-angiogenic environment which could result in a 
deficient repair process in the aging kidney [144]. 
Another factor in the decreased ability of the aging kidney to repair following injury may be the 
decreased expression of components of the cadherin/catenin complex that mediates cell-cell adhesion 
in the proximal tubule. Our laboratory has demonstrated that the expression of α(E)-catenin is 
decreased in the aging kidney [145,146]. Given the importance of this complex in establishing cell 
polarity and regulating the actin cytoskeleton, this deficiency may inhibit the complete recovery of the 
tubular epithelium in the aging kidney. This was supported by our recent study which demonstrated 
that loss of α(E)-catenin expression leads to down-regulation of BMP-7 and N-cadherin, decreasing 
repair in renal tubule epithelial cells due to alterations in cell migration [145,146]. 
Finally, Bonventre and coworkers have shown that a G2/M cell cycle arrest shifts the outcome from 
repair to fibrosis following AKI [147]. Mechanistically, the G2/M arrest is associated with activation 
of JNK, which then upregulates profibrotic cytokines, including TGF-β1 and CTGF; interestingly 
these are overxpressed in the aging kidney [114,143]. Rescue from this arrest, using pharmacological 
approaches, attenuates the fibrotic response. These results demonstrate a definitive link between 
deficient repair and progression to CKD in the kidney. 
6. Conclusions 
Renal aging is a complex multifactorial process which predisposes to AKI in the elderly population. 
Unfortunately, there is no effective therapy currently available for AKI. It is clear, however, that the 
increased susceptibility of the aging kidney to injury is complex and, most likely, cannot be accounted 
for by a single mechanism. This is highlighted by the findings that injury is increased, while repair is 
decreased in the aging kidney, and within each of these pathways there are many converging 
mechanisms at play. Hopefully, the deeper understanding of all the mechanisms underlying AKI in 
elderly patients will lead to progression in the development of preventive and protective interventions 
that decrease the dialysis-requiring AKI and potentiate the resolution of AKI. 
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